A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 + T Cell Epitopes

Xuedan He,Shiqi Zhou,Wei-Chiao Huang,Amal Seffouh,Moustafa T. Mabrouk,M. Thomas Morgan,Joaquin Ortega,Scott I. Abrams,Jonathan F. Lovell

DOI: https://doi.org/10.1021/acsnano.0c07680

IF: 17.1

2021-02-19

ACS Nano

Abstract:Short major histocompatibility complex (MHC) class I (MHC-I)-restricted peptides contain the minimal biochemical information to induce antigen (Ag)-specific CD8⁺ cytotoxic T cell responses but are generally ineffective in doing so. To address this, we developed a cobalt–porphyrin (CoPoP) liposome vaccine adjuvant system that induces rapid particleization of conventional, short synthetic MHC-I epitopes, leading to strong cellular immune responses at nanogram dosing. Along with CoPoP (to induce particle formation of peptides), synthetic monophosphoryl lipid A (PHAD) and QS-21 immunostimulatory molecules were included in the liposome bilayer to generate the "CPQ" adjuvant system. In mice, immunization with a short MHC-I-restricted peptide, derived from glycoprotein 70 (gp70), admixed with CPQ safely generated functional, Ag-specific CD8⁺ T cells, resulting in the rejection of multiple tumor cell lines, with durable immunity. When cobalt was omitted, the otherwise identical peptide and adjuvant components did not result in peptide binding and were incapable of inducing immune responses, demonstrating the importance of stable particle formation. Immunization with the liposomal vaccine was well-tolerated and could control local and metastatic disease in a therapeutic setting. Mechanistic studies showed that particle-based peptides were better taken up by antigen-presenting cells, where they were putatively released within endosomes and phagosomes for display on MHC-I surfaces. On the basis of the potency of the approach, the platform was demonstrated as a tool for <i>in vivo</i> epitope screening of peptide microlibraries comprising a hundred peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c07680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c07680</a>.Supporting methods; figures showing synthesis schemes, ¹H and ¹³C NMR and mass spectra, HPLC traces, cryo-electron micrographs, peptide bindings to liposomes, gating results, CPQ/A5 vaccination effects, impacts of PHAD, QS-21 and antigens, optional solubility tag effects, QS-21 and antigen dosage effects, liposomes draining, vaccine injection effects at multiple sites, macrophage uptake, PoP lipids coated on silica beads, liposome/peptide complexes, A5 with 2 his-tag released, fluorescence integrity, various length impacts of A5, QS-21 and peptide dose effects, CPQ as platform, details of peptide binding, cytotoxicities, Rragc385 DNA sequencing, and antitumor efficacy; tables listing ¹H shifts and assignments, ICP analysis, representative UV–vis absorptions, polydispersities and ζ potentials, A5 peptides, and properties of A5 related and synthetic peptides (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c07680/suppl_file/nn0c07680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the effectiveness of short - peptide - based cancer vaccines, especially for MHC - I - restricted short peptides (i.e., peptide segments that can activate CD8+ cytotoxic T lymphocytes). Due to their simplicity and directness, short peptides are theoretically an ideal choice for developing cancer vaccines, but they often have poor performance in practical applications, mainly because it is difficult to effectively generate a sufficient number and quality of antigen - specific CD8+ T cells. For this reason, the researchers have developed a vaccine adjuvant system (CPQ) based on cobalt porphyrin liposomes (CoPoP). This system can promote the granulation of short synthetic MHC - I epitopes, thereby triggering a strong cellular immune response at nano - doses. Through this system, the researchers hope to overcome the limitations of traditional short - peptide vaccines and provide a more effective cancer immunotherapy strategy.

Specifically, the paper addresses this problem in the following aspects:

1. **Granulation technology**: Utilize the spontaneous binding of CoPoP liposomes with short peptides containing a short poly - histidine tag (his - tag) to form stable particles. These particles can be better taken up by antigen - presenting cells (APCs), thereby enhancing the immune response.

2. **Adjuvant combination**: In addition to CoPoP, the CPQ system also contains synthetic monophosphoryl lipid A (PHAD) and QS - 21 immunostimulatory molecules. These two components work together to further enhance the immune effect of the vaccine.

3. **High efficiency at low doses**: Studies have shown that even at nano - level doses, short - peptide vaccines using the CPQ system can induce a strong functional CD8+ T - cell response, which is several orders of magnitude lower than the doses required in traditional pre - clinical studies.

4. **Wide applicability**: This vaccine not only performs well in preventive vaccine settings, being able to inhibit the growth of multiple tumor cell lines, but also shows the ability to control local and metastatic diseases in early therapeutic vaccine settings.

5. **Safety assessment**: The study also evaluated the safety of the CPQ/A5 vaccine, and the results showed that it has good tolerance and did not cause obvious side effects or toxic reactions.

Through the above methods, this study aims to provide an efficient short - peptide vaccine platform for the prevention and treatment of cancer, especially showing great potential in the discovery and screening of new peptide epitopes.